.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DI01_CeftobiproleMedocaril.CeftobiproleMedocaril

Information

Ceftobiprole medocaril is a cephalosporin antibiotic prodrug that is rapidly converted in vivo to its active form, ceftobiprole. It is used for the treatment of hospital-acquired and community-acquired pneumonia and has activity against a wide spectrum of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved in several countries in Europe and elsewhere, but not currently approved for use in the United States.

Pharmacokinetics

Pharmacokinetics in healthy adult subjects, with values based on a population pharmacokinetic analysis after intravenous infusion.

References

1. Torres, A, et al., & Pea, F (2016). Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. Clinical pharmacokinetics 55(12) 1507–1520. DOI:10.1007/s40262-016-0418-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/27272266

2. Rubino, CM, et al., & Hamed, K (2021). Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients. The Pediatric infectious disease journal 40(11) 997–1003. DOI:10.1097/INF.0000000000003296 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34533489

Revisions

• 06/2025 initial generated model